Quick Answer
VYNE Therapeutics Inc. reported Diluted EPS of $0.62 per share (loss) for fiscal year 2025.
VYNE Therapeutics Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.62 | +33.3% |
| 2024 | -$0.93 | +66.5% |
| 2023 | -$2.78 | +61.8% |
| 2022 | -$7.28 | +71.6% |
| 2021 | -$25.64 | -425.4% |
| 2020 | $7.88 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| June 30, 2025 | -$0.13 | +40.9% | +35.0% |
| March 31, 2025 | -$0.20 | -33.3% | +31.0% |
| September 30, 2024 | -$0.29 | +85.6% | -31.8% |
| June 30, 2024 | -$0.22 | +92.9% | -46.7% |
| March 31, 2024 | -$0.15 | +91.4% | +92.5% |
| September 30, 2023 | -$2.01 | +31.6% | +35.0% |
| June 30, 2023 | -$3.09 | -17.5% | -77.6% |
| March 31, 2023 | -$1.74 | -215.2% | +40.8% |
- VYNE Therapeutics Inc. showed an increase of +33.3% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, VYNE Therapeutics Inc.’s diluted eps has declined by 107.9% (from $7.88 per share to $0.62 per share (loss)).
- The most recent figure is from VYNE Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: